With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
A wave of commercial flight disruptions is pushing a new class of travelers toward private aviation, not for opulence but for reliability. We examine the shifting calculus of air travel and what a seat actually costs.
A special anti-corruption court in Dhaka has delivered a landmark verdict, sentencing former Prime Minister Sheikh Hasina to 10 years imprisonment and her British lawmaker niece to four years over illicit land allocations in a flagship housing project. The ruling intensifies the political turbulence ahead of crucial elections.
With a partial government shutdown underway, House Speaker Mike Johnson confronts a dual crisis: securing passage of a federal funding package and mediating an intensifying political battle over the scope and tactics of Immigration and Customs Enforcement operations.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Amid a volatile market, EFG International's consistent profit growth and significant insider holdings present a compelling case for stability-focused investors, setting it apart from riskier, loss-making ventures.
The Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a critical, if symbolic, step in implementing the U.S.-brokered ceasefire. The move follows intense diplomatic efforts and comes as the agreement enters a more complex second phase.
Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.
As the EU's landmark 'Next Generation' fund nears its final payout deadlines, its ambitious goal of modernizing the bloc's economy is being hampered by bureaucracy, skills gaps, and questions over long-term sustainability, despite pockets of innovation.
TransDigm Group's recent acquisitions of Stellant Systems and Jet Parts Engineering, totaling over $3 billion, have analysts debating whether the moves solidify its lucrative aftermarket strategy or stretch its leveraged balance sheet too thin ahead of a critical earnings season.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Long-term investors in German renewable energy developer PNE AG have seen their holdings plummet 42% over three years, starkly underperforming the broader market's 33% gain. Despite a 26% revenue growth, the stock's persistent weakness raises questions about underlying challenges in the sector and company-specific headwinds.
Certified financial planner and popular financial educator Kevin Lum outlines a crucial mindset shift for those nearing or in retirement, urging them to move beyond accumulation and toward purposeful living.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
As the FTSE 100 hits record highs, a broader rally in UK mid and small-cap indices is prompting a strategic rethink. Analysts debate whether these long-neglected shares, now showing historic undervaluation, are poised for a major comeback.
As gold and silver surged to record highs last month, Bitcoin's puzzling stagnation below $90,000 had traders searching for answers. A closer look at exchange order books reveals a deliberate play by large players to suppress price—a tactic that ultimately set the stage for last week's sharp decline.
Bitcoin experienced a sharp, V-shaped recovery after briefly tumbling near $74,000, a swing exacerbated by critically thin market liquidity. The move liquidated over half a billion dollars in leveraged positions, underscoring heightened volatility as traders navigate a market lacking depth.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
